

From: [Lynch, Andrea](#)
To: ["Allen, David \(ELS-HBE\)"; "Primo Lara"](#)
Cc: ["Janna Peterson"](#)
Subject: RE: Please read: Action required to comply with the NIH Public Access Policy
Date: Thursday, August 01, 2013 12:57:30 PM

Great! I will upload to the NIHMS system the final published version along with the below message indicating that we have your permission to upload that version.

With best regards,
Andrea

Andrea Lynch, MLIS | Scholarly Communication Librarian
[Lee Graff Medical & Scientific Library](#) | Get the latest library news; subscribe to our [blog!](#)

[City of Hope](#) | 1500 East Duarte Road | Duarte, CA 91010-3000
Phone 626-256-4673 x60520 | Fax 626-357-1929

From: Allen, David (ELS-HBE) [mailto:David.Allen@elsevier.com]
Sent: Thursday, August 01, 2013 11:53 AM
To: Primo Lara; Lynch, Andrea
Cc: Janna Peterson
Subject: RE: Please read: Action required to comply with the NIH Public Access Policy

Dear Dr. Lara,

As this was published under the old CIG license and at the time of publication, we specifically said that we'd provide the final PDF on request. I am attaching the PDF for you to use.

Dave

From: Primo Lara [mailto:Primo.Lara@ucdmc.ucdavis.edu]
Sent: Thursday, August 01, 2013 2:26 PM
To: Lynch, Andrea
Cc: Janna Peterson; Allen, David (ELS-HBE)
Subject: RE: Please read: Action required to comply with the NIH Public Access Policy

Alas - it might be tough to find the final Word version, I may have already deleted or archived it somewhere.

It doesn't state anywhere in the email that it will be a violation of the Elsevier's CTA if the PDF is uploaded. I'm copying David Allen, published of Clinical Lung Cancer on this email so he can comment.

Primo N. Lara, Jr., MD
Professor of Medicine
Associate Director for Translational Research
University of California Davis Comprehensive Cancer Center
4501 X Street, Suite 3016
Sacramento, CA 95817
Voice 916.734.3771
Fax 916.734.7946

From: "Lynch, Andrea" <alynch@coh.org>
To: 'Primo Lara' <Primo.Lara@ucdmc.ucdavis.edu>
Date: 08/01/2013 11:15 AM
Subject: RE: Please read: Action required to comply with the NIH Public Access Policy

It would be a violation of your copyright transfer agreement to load the published version.

Andrea

Andrea Lynch, MLIS | Scholarly Communication Librarian
[Lee Graff Medical & Scientific Library](#) | Get the latest library news; subscribe to our [blog!](#)

[City of Hope](#) | 1500 East Duarte Road | Duarte, CA 91010-3000
Phone 626-256-4673 x60520 | Fax 626-357-1929

From: Primo Lara [<mailto:Primo.Lara@ucdmc.ucdavis.edu>]
Sent: Thursday, August 01, 2013 11:14 AM
To: Lynch, Andrea
Subject: Re: Please read: Action required to comply with the NIH Public Access Policy

Can't you just upload the PDF? I don't think I can find the final Word version of the manuscript.

Primo N. Lara, Jr., MD
Professor of Medicine
Associate Director for Translational Research
University of California Davis Comprehensive Cancer Center
4501 X Street, Suite 3016
Sacramento, CA 95817
Voice 916.734.3771
Fax 916.734.7946

From: "Lynch, Andrea" <alynch@coh.org>
To: "primo.lara@ucdmc.ucdavis.edu" <primo.lara@ucdmc.ucdavis.edu>
Cc: "Newman, Edward" <ENewman@coh.org>, "david.gandara@ucdmc.ucdavis.edu" <david.gandara@ucdmc.ucdavis.edu>
Date: 08/01/2013 09:11 AM
Subject: Please read: Action required to comply with the NIH Public Access Policy

Dear Dr. Lara,

I believe this paper falls under the NIH Public Access Policy, since it acknowledged Dr. Gandara's NIH contract N01 CM-62209, and that is why I'm attempting to get it processed for PubMed Central. If you send me the final peer-reviewed author manuscript along with the 3 tables and figure of the below article, I will upload this paper to the NIH Manuscript Submission system. Elsevier will not do this for us; please see below.

Once reviewed by Dr. Lara, it will take 8 weeks for NIH to perform QA review. Therefore the PMCID will not be issued for at least 2.5 months.

Lara PN Jr, Longmate J, Reckamp K, Gitlitz B, Argiris A, Ramalingam S, Belani CP, Mack PC, Lau DH, Koczywas M, Wright JJ, Shepherd FA, Leighl N, Gandara DR. Randomized Phase II Trial of Concurrent Versus Sequential Bortezomib Plus Docetaxel in Advanced Non-Small-Cell Lung Cancer: A California Cancer Consortium Trial. Clin Lung Cancer. 2011;12:33-7.

Please let me know what questions you may have.

With best regards,
Andrea

Andrea Lynch, MLIS | Scholarly Communication Librarian
[Lee Graff Medical & Scientific Library](#) | Get the latest library news; subscribe to our [blog!](#)

[City of Hope](#) | 1500 East Duarte Road | Duarte, CA 91010-3000
Phone 626-256-4673 x60520 | Fax 626-357-1929

From: EP Support [<mailto:support@elsevier.com>]
Sent: Thursday, August 01, 2013 2:50 AM
To: Lynch, Andrea
Subject: [Nihms-helpdesk] FW: Request to place paper into PubMed Central workflow [Reference: 130729-007662]

Subject

[Nihms-helpdesk] FW: Request to place paper into PubMed Central workflow

Discussion

Response Via Email (Carole Hardy)

01/08/2013 10:50 AM

Dear Andrea

Thank you for your enquiry.

After investigation, I can see this article was published in Jan 2011 and Elsevier took the title from March 2011, as such we do not have the details on our system to upload the information.

I have been advised, the author is able to upload the manuscript themselves.
"Articles published in journals prior to Elsevier acquiring the title - Please advise the author that they can upload the article to NIHMS themselves. PTS will not hold this information therefore we cannot start any triggers from our side."

Please see information on the link below, some guidelines on how to deposit the manuscript your self

National Institute of Health US (NIH)
http://support.elsevier.com/app/answers/detail/a_id/1351

Should you have any questions, please do not hesitate to contact me.

Kind Regards

Carole Hardy
Customer Service Advisor
Elsevier Support
EMEA

Auto-Response

29/07/2013 09.28 PM

Dear Customer,

Thank you for contacting Journals Submission Customer Support. This is an automated acknowledgement to confirm that we have received your email.

For all future correspondence please quote your unique reference number provided in the subject header of this email. Our current response time is a maximum of 1 working day.

If you have not already visited our self-help site, please go to <http://support.elsevier.com> where you can find frequently asked questions, online tutorials and instructions which may help to resolve your query.

Regards,

Journals Submission Customer Support

Customer By Email (Andrea Lynch)

29/07/2013 09.28 PM

To Whom It May Concern,

I need help to track down this paper in the NIHMS system. According to the NIHMS Helpdesk, it has not been submitted by Elsevier. Back in June, Julie Markosian was working on getting this paper submitted.

Would you be able to provide me with an update? Thank you in advance!

With best regards,
Andrea

Thank you, Abigail. I will follow-up with Elsevier.

Andrea

Andrea Lynch, MLIS | Scholarly Communication Librarian
Lee Graff Medical & Scientific Library | Get the latest library news; subscribe to our blog!

City of Hope | 1500 East Duarte Road | Duarte, CA 91010-3000
Phone 626-256-4673 x60520 | Fax 626-357-1929

-----Original Message-----

From: Acland, Abigail (NIH/NLM/NCBI) [C] [mailto:aclanda@ncbi.nlm.nih.gov]

Sent: Monday, June 10, 2013 3:13 PM

To: Lynch, Andrea; NLM/NCBI nihms-helpdesk

Subject: Re: [Nihms-helpdesk] FW: Request to place paper into PubMed Central workflow [Reference: 111130-000017]

Andrea,

I have no records matching this title or PMID in NIHMS. It does not appear to have been submitted to our system.

Thank you,

Abigail Acland, contractor

NIHMS helpdesk

On 6/10/13 5:46 PM, "Lynch, Andrea" <alynch@coh.org> wrote:

>To Whom It May Concern,

>

>I can't find this paper in the NIHMS system searching on the PMID:

>21273177. Would you please confirm that this paper has been deposited

>to the system by Elsevier?

>

>Thank you,

>Andrea

>_____

>____

>____

>Andrea Lynch, MLIS | Scholarly Communication Librarian Lee Graff

>Medical & Scientific Library | Get the latest library news; subscribe

>to our blog!

>

>City of Hope | 1500 East Duarte Road | Duarte, CA 91010-3000 Phone

>626-256-4673 x60520 | Fax 626-357-1929

>

>

>-----Original Message-----

>From: EP Support [mailto:support@elsevier.com]

>Sent: Monday, December 05, 2011 4:14 PM

>To: Lynch, Andrea

>Subject: Request to place paper into PubMed Central workflow [Reference:

>111130-000017]

>

>

>Subject

>-----

>Request to place paper into PubMed Central workflow

>

>

>Discussion

>-----

>Response Via Email(Julie) - 06/12/2011 12.14 AM

>

>Hello,

>

>I have made the request, Dr. Lara will receive an e-mail shortly from

>NIH with further instructions. Thank you again for your patience.

>

>Kind regards,

>

>Julie Markosian

>EP Customer Support

>Supporting our Customers: <http://support.elsevier.com>

>

>.....

>Customer By Email (Andrea Lynch) - 02/12/2011 09.27 PM

>

>Dear Julie,

>

>This is indeed wonderful news! I'm so excited that you and your

>colleagues will help us with depositing this paper.

>

>Here's the information:

>

>Lara PN Jr, Longmate J, Reckamp K, Gitlitz B, Argiris A, Ramalingam S,
>Belani CP, Mack PC, Lau DH, Koczywas M, Wright JJ, Shepherd FA, Leighl
>N, Gandara DR. Randomized Phase II Trial of Concurrent Versus
>Sequential Bortezomib Plus Docetaxel in Advanced Non-Small-Cell Lung
>Cancer: A California Cancer Consortium Trial. Clin Lung Cancer.
>2011;12:33-7.

>a. This paper acknowledges NIH funding: N01 CM-62209; PI: Dr. D.R.
>Gandara b. DOI: 10.3816/CLC.2011.n.004

>

>Thank you so much. Please let me know if you need anything else.

>

>With best regards,
>Andrea

>

>_____

>_____

>Andrea Lynch, MLIS | Scholarly Communication Librarian Lee Graff
>Medical & Scientific Library | Get the latest library news; subscribe
>to our blog!

>

>City of Hope | 1500 East Duarte Road | Duarte, CA
>91010-3000
>Phone 626-256-4673 x60520 | Fax 626-357-1929

>

>

>

>

>

>-----

>SECURITY/CONFIDENTIALITY WARNING: This message and any attachments are
>intended solely for the individual or entity to which they are addressed.
>This communication may contain information that is privileged,
>confidential, or exempt from disclosure under applicable law (e.g.,
>personal health information, research data, financial information).
>Because this e-mail has been sent without encryption, individuals other
>than the intended recipient may be able to view the information,
>forward it to others or tamper with the information without the
>knowledge or consent of the sender. If you are not the intended
>recipient, or the employee or person responsible for delivering the
>message to the intended recipient, any dissemination, distribution or
>copying of the communication is strictly prohibited. If you received
>the communication in error, please notify the sender immediately by
>replying to this message and deleting the message and any accompanying
>files from your system. If, due to the security risks, you do not wish
>to receive further communications via e-mail, please reply to this
>message and inform the sender that you do not wish to receive further e-mail from the sender.

>

>-----

>

>.....
>Response Via Email(Julie) - 02/12/2011 07.55 PM

>

>Dear Andrea,

>

>Thank you for your patience.

>

>I have good news! Please reply to this e-mail with everything I should

>need to know about the article so we can track down the final version.
>We will still upload it to NIH on your behalf.
>
>Please include Author's names, volume/issue numbers, and page numbers.
>
>If responding to this e-mail, please ensure that the reference number
>remains in the subject line.
>
>Should you have any additional questions or concerns, please visit our
>self-help site at: <http://support.elsevier.com/>. Here you will be able
>to search for solutions on a range of topics, find answers to
>frequently asked questions and learn more about EES via interactive
>tutorials. You will also find our 24/7 support contact details should
>you need further assistance from one of our customer service representatives.
>
>Yours sincerely,
>
>Julie Markosian
>Elsevier Customer Support
>
>Copyright 2008 Elsevier Limited. All rights reserved.
>How are we doing? If you have any feedback on our customer service we
>>would be happy to receive your comments at
>customerfeedback@elsevier.com
>
>.....
>Response Via Email(Julie) - 01/12/2011 01.14 AM
>
>Dear Andrea,
>
>Thank you for your e-mail and for your patience.
>
>I have been working on this for you and there is no simple answer I am
>afraid. These circumstance are somewhat unique so I want to make sure I
>provide you with the correct answer. Once I have more information I
>will be in touch.
>
>If responding to this e-mail, please ensure that the reference number
>remains in the subject line.
>
>Should you have any additional questions or concerns, please visit our
>self-help site at: <http://support.elsevier.com/>. Here you will be able
>to search for solutions on a range of topics, find answers to
>frequently asked questions and learn more about EES via interactive
>tutorials. You will also find our 24/7 support contact details should
>you need further assistance from one of our customer service representatives.
>
>Yours sincerely,
>
>Julie Markosian
>Elsevier Customer Support
>
>Copyright 2008 Elsevier Limited. All rights reserved.
>How are we doing? If you have any feedback on our customer service we
>>would be happy to receive your comments at
>customerfeedback@elsevier.com
>
>.....
>Customer By Email (Andrea Lynch) - 30/11/2011 12.12 AM

>
>I'm resending this message in hopes that someone will get back to me
>about it.

>
>Thank you in advance!

>
>With best regards,
>Andrea

> _____
> _____
> _____

>Andrea Lynch, MLIS | Scholarly Communication Librarian Lee Graff
>Medical & Scientific Library | Get the latest library news; subscribe
>to our blog!

>
>City of Hope | 1500 East Duarte Road | Duarte, CA 91010-3000 Phone
>626-256-4673 x60520 | Fax 626-357-1929

>
>
>Importance: High

>
>To Whom It May Concern,

>
>Given the impossibility for me to contact a CGI representative (because
>they have gone out of business; none of their contact, about,
>subscribe, advertise pages provide contact information) and since
>Elsevier holds the copyright to the article, is there any way someone
>at Elsevier can help us with this paper?

>
>The corresponding author, Dr. Lara, is unable to find the version we
>need to upload to the NIH Manuscript Submission system. Would Elsevier
>be willing to make an exemption in order to allow the final, published
>version to be submitted?

>
>Thank you so much in advance for your consideration. Any assistance you
>can provide would be most helpful.

>
>With best regards,
>Andrea

> _____
> _____
> _____

>Andrea Lynch, MLIS | Scholarly Communication Librarian Lee Graff
>Medical & Scientific Library | Get the latest library news; subscribe
>to our blog!

>
>City of Hope | 1500 East Duarte Road | Duarte, CA 91010-3000 Phone
>626-256-4673 x60520 | Fax 626-357-1929

>
>
>-----Original Message-----

>From: EP Support [mailto:support@elsevier.com]
>Sent: Wednesday, August 10, 2011 3:33 PM
>To: Lynch, Andrea

>
>.....

>
>=====

>This communication is confidential and may be privileged. Any

>unauthorized use or dissemination of this message in whole or in part
>is strictly prohibited and may be unlawful. If you receive this message
>by mistake, please notify the sender by return email and delete this
>message from your system. Elsevier B.V. (including its group companies)
>shall not be liable for any improper or incomplete transmission of the
>information contained in this communication or delay in its receipt.
>Any price quotes contained in this communication are merely indicative
>and may not be relied upon by the individual or entity receiving it.
>Any proposed transactions or quotes contained in this communication
>will not result in any legally binding or enforceable obligation or
>give rise to any obligation for reimbursement of any fees, expenses,
>costs or damages, unless an express agreement to that effect has been
>agreed upon, delivered and executed by the parties.
>©2011, Elsevier BV. All rights reserved.

>
>
>
>
>

>-----
>*SECURITY/CONFIDENTIALITY WARNING:
>This message and any attachments are intended solely for the individual
>or entity to which they are addressed. This communication may contain
>information that is privileged, confidential, or exempt from disclosure
>under applicable law (e.g., personal health information, research data,
>financial information). Because this e-mail has been sent without
>encryption, individuals other than the intended recipient may be able
>to view the information, forward it to others or tamper with the
>information without the knowledge or consent of the sender. If you are
>not the intended recipient, or the employee or person responsible for
>delivering the message to the intended recipient, any dissemination,
>distribution or copying of the communication is strictly prohibited. If
>you received the communication in error, please notify the sender
>immediately by replying to this message and deleting the message and
>any accompanying files from your system. If, due to the security risks,
>you do not wish to receive further communications via e-mail, please
>reply to this message and inform the sender that you do not wish to
>receive further e-mail from the sender. (fpc5p)

>-----
>
>

>Nihms-helpdesk mailing list
>Nihms-helpdesk@ncbi.nlm.nih.gov
><http://www.ncbi.nlm.nih.gov/mailman/listinfo/nihms-helpde>

This communication is confidential and may be privileged. Any unauthorized use or dissemination of this message in whole or in part is strictly prohibited and may be unlawful. If you receive this message by mistake, please notify the sender by return email and delete this message from your system. Elsevier B.V. (including its group companies) shall not be liable for any improper or incomplete transmission of the information contained in this communication or delay in its receipt. Any price quotes contained in this communication are merely indicative and may not be relied upon by the individual or entity receiving it. Any proposed transactions or quotes contained in this communication will not result in any legally binding or enforceable obligation or give rise to any obligation for reimbursement of any fees, expenses, costs or damages, unless an express agreement to that effect has been agreed upon, delivered and executed by the parties. ©2013, Elsevier BV. All rights reserved.

"RandomizedPhaseIITrialofConcurrentVersusSequentialBortezomibPlusDocetaxelinAdvancedNon-Small-CellLungCancer.pdf" deleted by Primo Lara/PHY/HS/UCD]